$MSCI

Wiechmann Andrew C. sold $272K of MSCI

Wiechmann Andrew C. (Chief Financial Officer) sold 450 shares of MSCI Inc. (MSCI) at $604.56 ($0.27M total) on 2026-06-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Wiechmann Andrew C.
Published Jun 12, 2026, 8:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 12, 2026, 8:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MSCI
Neutral
high confidence
Mentioned
$MSCI
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MSCINeutralLow
01

Why it matters

The newest fact is the CFO’s open-market sale of 450 shares at ~$604.56/share under a pre-arranged 10b5-1 plan; no other MSCI-specific developments are provided.

02

Market read

Primarily sentiment/positioning noise rather than a fundamental catalyst.

03

What to watch

The filing does not indicate intent beyond the plan; without additional context (e.g., multiple consecutive sales), signal-to-noise is low.

Relevance 3/10Novelty 2/10Timing: Filed 2026-06-12; sale executed 2026-06-10.

Background

The article is an SEC Form 4 insider transaction disclosure for MSCI, reported from SEC EDGAR.

Company-level read

Ticker impact

$MSCINeutralHigh confidence
Context

MSCI CFO Andrew C. Wiechmann sold 450 shares (~$272K) via an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

This is a Form 4 insider sale with a stated 10b5-1 plan, and the article provides no new company-specific operational or financial catalyst.

Market effects

Minimal; insider transaction does not reset sector expectations.

None indicated.

None indicated.

Counterpoint

Even 10b5-1 sales can coincide with private views on valuation or liquidity needs; traders may still watch for follow-on insider activity.

Key entities

  • MSCI Inc.

    Company whose CFO filed the Form 4 insider sale disclosure.

  • Andrew C. Wiechmann

    MSCI CFO who sold 450 shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

India's Swiggy pares gains ahead of exit from MSCI indexes

Swiggy's shares closed 2.5% higher on Friday, after rising as much as 5.61%, ahead of being removed from MSCI indexes. The firm faces an estimated $360 million in passive outflows, according to Nuvama's Abhilash Pagaria. Swiggy's shares have fallen 28.5% this year, underperforming the Nifty mid-cap 100 index.

MedAI 8/10

MSCI August Rebalance and Jio IPO Approval to Test Market

MSCI's August 2026 index rebalance, effective September 1, 2026, will shift $1.5B in passive funds, adding Laurus Labs, Lenskart, Adani Energy, and Billionbrains, while removing Balkrishna, SBI Cards, and Astral. Jio Platforms' IPO, approved by SEBI, aims to raise ₹27,500 crore. New closing auction rules may increase volatility.

$MSTRMed

MicroStrategy Bitcoin: MSCI Index Review Could Pressure Shares

MSCI is reviewing rules that could remove MicroStrategy from global equity indexes, focusing on companies primarily engaged in asset accumulation. MicroStrategy shares rose 35% in a week but are down 60% year-over-year. The review uses five financial metrics to assess eligibility, potentially affecting demand and capital access for MicroStrategy's Bitcoin purchases.

$MSCIHighAI 8/10

Are Wall Street Analysts Bullish on MSCI Stock?

MSCI Inc. (MSCI), a data and analytics provider, has underperformed the broader market over the past year. Its shares fell 10.1% on July 21 after raising its 2026 operating expense forecast, citing higher costs. Analysts expect MSCI's adjusted EPS to grow 13.5% YoY to $19.61. The consensus rating is 'Strong Buy' with a mean price target of $690.44, a 22.5% premium to current levels.